Our study observed that in RA patients with high levels of Th2, Th17, and Th17/Treg on the basis of the original treatment, exogenous TCZ and low dose of IL-2 can rapidly and safely reduce the DAS28 score and alleviate the disease in a short period, effectively promote the moderate proliferation of Tregs and reduce the level of Th cells, which is consistent with the previous results of TCZ combined with other DMARDs (42). This evidence concerns the gene IL2 and rheumatoid arthritis.